---
title: "CRIS: Emavusertib shows strong response rates in PCNSL and advances in CLL, pending further funding"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293464781.md"
description: "Updated data show emavusertib achieves a 71% ORR in BTKi-naïve and 26% ORR in BTKi-experienced PCNSL patients, with promising early results in CLL. Regulatory guidance supports potential accelerated approval, but continued development depends on securing additional funding.Original document: Curis, Inc. [CRIS] Press release — Jul. 22 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-22T11:15:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293464781.md)
  - [en](https://longbridge.com/en/news/293464781.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293464781.md)
generator: "portal-rs"
---

# CRIS: Emavusertib shows strong response rates in PCNSL and advances in CLL, pending further funding

Updated data show emavusertib achieves a 71% ORR in BTKi-naïve and 26% ORR in BTKi-experienced PCNSL patients, with promising early results in CLL. Regulatory guidance supports potential accelerated approval, but continued development depends on securing additional funding.

Original document: Curis, Inc. \[CRIS\] Press release — Jul. 22 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [CRIS.US](https://longbridge.com/en/quote/CRIS.US.md)

## Related News & Research

- [CRIS: Emavusertib shows superior efficacy and safety in NHL, CLL, and AML, advancing in registrational trials](https://longbridge.com/en/news/293485845.md)
- [Curis notifies press release availability on positive emavusertib update](https://longbridge.com/en/news/293462544.md)
- [KURA: KOMZIFTI leads new patient starts in acute leukemia, with major data and expansion ahead](https://longbridge.com/en/news/298474937.md)
- [SNDX: Dominant AML market share, advancing pivotal trials, and expanding pipeline in oncology and fibrosis](https://longbridge.com/en/news/298611451.md)
- [The Bull Case For Natera (NTRA) Could Change Following New Signatera Lymphoma Data And Komen Partnership](https://longbridge.com/en/news/298111249.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**